文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

18F-FDG PET-CT 检测的基线总代谢肿瘤体积和总病变糖酵解预测 T 细胞淋巴母细胞淋巴瘤的结局。

Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.

机构信息

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

Cancer Res Treat. 2021 Jul;53(3):837-846. doi: 10.4143/crt.2020.123. Epub 2020 Dec 2.


DOI:10.4143/crt.2020.123
PMID:33285054
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8291183/
Abstract

PURPOSE: There is no optimal prognostic model for T-cell lymphoblastic lymphoma (T-LBL). Here, we discussed the predictive value of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in T-LBL. MATERIALS AND METHODS: Thirty-seven treatment naïve T-LBL patients with PET-CT scans were enrolled. TMTV was obtained using the 41% maximum standardized uptake value (SUVmax) threshold method, and TLG was measured as metabolic tumor volume multiplied by the mean SUV. Progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier curves and compared by the log-rank test. RESULTS: The optimal cutoff values for SUVmax, TMTV, and TLG were 12.7, 302 cm3, and 890, respectively. A high SUVmax, TMTV, and TLG indicated a shorten PFS and OS. On multivariable analysis, TMTV ≥ 302 cm3, and central nervous system (CNS) involvement predicted inferior PFS, while high SUVmax, TLG and CNS involvement were associated with worse OS. Subsequently, we generated a risk model comprising high SUVmax, TMTV or TLG and CNS involvement, which stratified the population into three risk groups, which had significantly different median PFS of not reached, 14 months, and 7 months for low-risk group, mediate-risk group, and high-risk group, respectively (p < 0.001). Median OS were not reached, 27 months, and 13 months, respectively (p < 0.001). CONCLUSION: Baseline SUVmax, TMTV, and TLG measured on PET-CT are strong predictors of worse outcome in T-LBL. A risk model integrating these three parameters with CNS involvement identifies patients at high risk of disease progression.

摘要

目的:目前尚不存在用于 T 细胞淋巴母细胞淋巴瘤(T-LBL)的最佳预后模型。在此,我们探讨了 18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(PET-CT)上测量的总代谢肿瘤体积(TMTV)和总病变糖酵解(TLG)的预测价值。

材料与方法:纳入了 37 例初治 T-LBL 患者,他们均接受了 PET-CT 扫描。使用 41%最大标准化摄取值(SUVmax)阈值法获取 TMTV,将代谢肿瘤体积乘以平均 SUV 来测量 TLG。通过 Kaplan-Meier 曲线分析无进展生存期(PFS)和总生存期(OS),并通过对数秩检验进行比较。

结果:SUVmax、TMTV 和 TLG 的最佳截断值分别为 12.7、302cm3 和 890。SUVmax、TMTV 和 TLG 较高提示 PFS 和 OS 较短。多变量分析显示,TMTV≥302cm3 和中枢神经系统(CNS)受累预示着较差的 PFS,而 SUVmax、TLG 和 CNS 受累与较差的 OS 相关。随后,我们构建了一个包含 SUVmax、TMTV 或 TLG 以及 CNS 受累的风险模型,该模型将人群分为低危组、中危组和高危组三个风险组,低危组、中危组和高危组的中位 PFS 分别为未达到、14 个月和 7 个月,差异具有统计学意义(p<0.001)。中位 OS 分别为未达到、27 个月和 13 个月,差异具有统计学意义(p<0.001)。

结论:PET-CT 上测量的基线 SUVmax、TMTV 和 TLG 是 T-LBL 患者预后不良的有力预测指标。将这三个参数与 CNS 受累相结合的风险模型可识别出疾病进展风险高的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6688/8291183/498579640dbc/crt-2020-123f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6688/8291183/94ace4858879/crt-2020-123f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6688/8291183/b34ae2e92972/crt-2020-123f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6688/8291183/498579640dbc/crt-2020-123f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6688/8291183/94ace4858879/crt-2020-123f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6688/8291183/b34ae2e92972/crt-2020-123f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6688/8291183/498579640dbc/crt-2020-123f3.jpg

相似文献

[1]
Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.

Cancer Res Treat. 2021-7

[2]
Prognostic Values of Baseline F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma.

Biomed Res Int. 2020

[3]
[F-FDG PET/CT Metabolic Parameters and Circulating Tumour DNA Mutation Abundance in Diffuse Large B-Cell Lymphoma: Correlation and Survival Analysis].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023-12

[4]
Metabolic tumor burden on baseline F-FDG PET/CT improves risk stratification in pediatric patients with mature B-cell lymphoma.

Eur J Nucl Med Mol Imaging. 2019-6-11

[5]
Prognostic value of metabolic tumour volume on baseline F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Eur J Nucl Med Mol Imaging. 2019-4-2

[6]
Prognostic value of baseline F-FDG PET/CT metabolic parameters in paediatric lymphoma.

J Med Imaging Radiat Oncol. 2020-2

[7]
Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.

Oncotarget. 2016-12-13

[8]
Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma.

Cancer Res Treat. 2019-3-12

[9]
[Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].

Zhonghua Zhong Liu Za Zhi. 2018-7-23

[10]
[F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy.

Eur J Nucl Med Mol Imaging. 2024-7

引用本文的文献

[1]
A novel prognostic model utilizing TMTV and SUVmax from F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma.

BMC Cancer. 2025-3-3

[2]
Prognostic value of F-FDG PET/CT tumor metabolic parameters and Ki-67 in pre-treatment diffuse large B-cell lymphoma.

Quant Imaging Med Surg. 2024-1-3

[3]
Clinical and prognostic role of 2-[F]FDG PET/CT and sarcopenia in treatment-naïve patients with T-cell lymphoblastic lymphoma.

Ann Hematol. 2022-12

[4]
PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T-Cell Lymphoblastic Lymphoma.

Contrast Media Mol Imaging. 2022

[5]
Prediction of prognosis and pathologic grade in follicular lymphoma using F-FDG PET/CT.

Front Oncol. 2022-7-28

[6]
Prognostic Value of Heterogeneity Index Derived from Baseline F-FDG PET/CT in Mantle Cell Lymphoma.

Front Oncol. 2022-4-14

[7]
Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.

Blood Res. 2022-4-30

[8]
The Role of Pre-therapeutic F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection.

Front Med (Lausanne). 2022-1-21

[9]
Prognostic significance of clinical characteristics and Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma.

J Int Med Res. 2022-1

[10]
Prognostic value of baseline total metabolic tumour volume of F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma.

EJNMMI Res. 2021-7-15

本文引用的文献

[1]
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.

Blood. 2018-2-1

[2]
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.

Eur J Nucl Med Mol Imaging. 2018-1-17

[3]
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Blood. 2017-11-16

[4]
Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.

J Nucl Med. 2017-9-1

[5]
Predictive value of F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial.

Eur J Nucl Med Mol Imaging. 2017-7-21

[6]
Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators.

Exp Hematol. 2017-7

[7]
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.

J Clin Oncol. 2016-10-20

[8]
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.

Clin Cancer Res. 2016-3-2

[9]
Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.

Eur J Nucl Med Mol Imaging. 2016-7

[10]
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).

Ann Oncol. 2016-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索